Compare ASPS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | PRLD |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.9M | 69.1M |
| IPO Year | N/A | 2020 |
| Metric | ASPS | PRLD |
|---|---|---|
| Price | $7.06 | $2.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 24.0K | ★ 495.7K |
| Earning Date | 10-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | $10,500,000.00 |
| Revenue This Year | $38.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,046.65 | ★ N/A |
| Revenue Growth | 10.68 | ★ 250.00 |
| 52 Week Low | $4.92 | $0.61 |
| 52 Week High | $15.96 | $4.22 |
| Indicator | ASPS | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 64.07 |
| Support Level | $6.80 | $2.37 |
| Resistance Level | $7.53 | $3.00 |
| Average True Range (ATR) | 0.42 | 0.28 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 59.13 | 79.65 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.